This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D69.1 | Synonyms: platelet dysfunction, platelet function defects, Platelet function disorders, Qualitative platelet disorders
In 1882, the Italian Giulio Bizzozero first described platelets (thrombocytes) as a cellular component playing a key role in thrombus formation. Later, Duke (1910) introduced a method for clinically assessing platelet function through the bleeding time test. Initially, a decreased platelet count was recognized as the main cause of bleeding tendency, but as patients with a bleeding tendency despite a normal platelet count were later reported, the concept of platelet function abnormalities emerged.
From the mid-20th century onward, advances in electron microscopy and biochemical techniques elucidated in detail the internal structure (dense granules, alpha granules, surface-connected canalicular system, etc.) and function of platelets. In the 1960s–70s, various platelet function abnormalities such as Glanzmann thrombasthenia (GP IIb/IIIa deficiency), Bernard-Soulier syndrome (GP Ib deficiency), and platelet granule disorders were described at the molecular level. These discoveries became the basis for systematically classifying platelet function disorders into receptor defects, granule defects, signal transduction defects, and so on.
Since the 1990s, the PFA-100 (Platelet Function Analyzer-100) and platelet aggregation tests (whole blood impedance method, turbidimetric method) have become established as the standard for platelet function assessment. Compared with the traditional bleeding time test (Duke method, Ivy method), they have higher reproducibility and are easier to standardize, and are used for screening and diagnosis of various congenital and acquired platelet function abnormalities.
Congenital platelet function disorders are caused by genetic defects in proteins involved in platelet function.
| Classification | Representative disease | Defective protein/gene |
|---|---|---|
| Receptor defects | Glanzmann thrombasthenia | GP IIb/IIIa (ITGA2B, ITGB3) |
| Receptor defects | Bernard-Soulier syndrome | GP Ib-IX-V complex (GP1BA, GP1BB, GP9) |
| Receptor defects | Collagen receptor deficiency | GP Ia/IIa, GP VI |
| Granule defects | Gray platelet syndrome (GPS) | Alpha granule deficiency (NBEAL2) |
| Granule defects | Delta storage pool disease | Dense granule deficiency (HPS1-10, etc.) |
| Signal transduction defects | TXA2 receptor defect | Thromboxane A2 receptor |
Drugs: aspirin (irreversible COX-1 inhibition), P2Y12 antagonists (clopidogrel, ticagrelor), NSAIDs, antibiotics (penicillins), SSRIs, etc. inhibit platelet function. Systemic diseases: uremia, liver cirrhosis, myelodysplastic syndrome, polycythemia vera, essential thrombocythemia, paraproteinemia (multiple myeloma, MGUS). Other: extracorporeal circulation (cardiopulmonary bypass), massive transfusion, von Willebrand disease.
Congenital platelet function disorders are inherited in an autosomal recessive (Glanzmann thrombasthenia, Bernard-Soulier syndrome, gray platelet syndrome, etc.) or autosomal dominant (some alpha SPD, MYH9-related disorders, GFI1B-related GPS) manner. Rarely, X-linked inheritance (GATA-1 variants, accompanying Wiskott-Aldrich syndrome) has also been reported.
Major genes associated with platelet function disorders include ITGA2B (GP IIb), ITGB3 (GP IIIa), GP1BA, GP1BB, GP9 (Bernard-Soulier), NBEAL2 (gray platelet syndrome), and HPS1–10 (Hermansky-Pudlak syndrome). With advances in next-generation sequencing (NGS) technology, new causative genes continue to be discovered.
Acquired platelet function disorders are more common, but a congenital platelet function disorder should be suspected when there is a bleeding tendency from early childhood, a family history, and no history of drug exposure. Molecular genetic testing enables an accurate diagnosis, which is essential for genetic counseling and treatment planning.
Congenital platelet function disorders are rare diseases. The prevalence of Glanzmann thrombasthenia is estimated at less than about 1 per million, and Bernard-Soulier syndrome is at a similar level. Platelet storage pool deficiency, including dense granule deficiency, is relatively common among congenital platelet function disorders. However, incidence is higher in the Middle East, South Asia, and some European countries where consanguineous marriage is common.
Acquired platelet function abnormalities due to taking antiplatelet drugs such as aspirin are very common. Worldwide, users of aspirin for cardiovascular disease prevention number in the hundreds of millions. Platelet function abnormalities due to uremia are commonly observed in patients with chronic kidney disease and contribute importantly to the bleeding tendency of dialysis patients.
In Korea, congenital platelet function disorders are registered and managed as rare diseases. Acquired causes (drug-induced, associated with systemic disease) are more common, and with the growing population taking antiplatelet drugs, the importance of preoperative platelet function assessment is being highlighted. Accurate domestic prevalence statistics are lacking due to insufficient systematic research.
Platelet function broadly consists of the stages of adhesion, activation, aggregation, and secretion. When collagen and von Willebrand factor (vWF) are exposed upon vascular endothelial injury, platelets adhere via GP Ib (vWF binding) and GP Ia/IIa, GP VI (collagen binding) on the platelet surface. Subsequently, platelets are activated by activating factors such as ADP, thromboxane A2, and thrombin, and GP IIb/IIIa (αIIbβ3) mediates platelet-to-platelet aggregation using fibrinogen as a bridge.
GP IIb/IIIa deficiency (Glanzmann): inability to bind fibrinogen, so platelets cannot aggregate. GP Ib-IX-V deficiency (Bernard-Soulier): inability to adhere to the vessel wall via vWF, increased platelet size (giant platelets). Collagen receptor deficiency: inability of collagen to activate platelets.
Dense granule deficiency: ADP, serotonin, and calcium are not stored, so secondary wave aggregation cannot occur. Alpha granule deficiency: inability to secrete fibrinogen, vWF, P-selectin, platelet factor 4, etc. As a result, amplification of platelet activation signals is reduced.
Aspirin irreversibly acetylates COX-1, inhibiting thromboxane A2 synthesis. Uremic toxins (guanidinosuccinic acid, methyl guanidine, etc.) reduce platelet function through inhibition of GP IIb/IIIa function and oxidative stress. In liver cirrhosis, the mechanism is excessive production of nitric oxide (NO) and prostacyclin (PGI2), which inhibit platelet function.
Platelet function disorders mainly present with a pattern of mucosal bleeding: nosebleeds (epistaxis), gum bleeding, menorrhagia (in women), gastrointestinal bleeding. Skin petechiae and purpura occur, but the platelet count is normal or mildly decreased. Excessive or delayed bleeding after surgery, tooth extraction, childbirth, or trauma is characteristic, and recurrent, unpredictable bleeding interferes with daily life.
Mild: excessive bleeding only with surgery or trauma, no major interference with daily life. Moderate: recurrent spontaneous mucosal bleeding, anemia may occur. Severe (e.g., Glanzmann thrombasthenia): serious bleeding from early infancy (including intracerebral hemorrhage), repeated transfusions required. Bleeding severity is objectively assessed using bleeding assessment scores (ISTH-BAT, MCMDM-1, etc.).
Cases due to acquired causes (aspirin, etc.) usually involve mild bleeding and improve when the cause is removed. However, during the perioperative period, even mild functional abnormalities can lead to a significant bleeding risk.
Skin petechiae, purpura, ecchymosis. Mucosal pallor (when accompanied by anemia). Traces of bleeding in the nasal cavity. Bleeding spots on the oral mucosa. Splenomegaly may rarely accompany Bernard-Soulier syndrome.
Complete blood count (CBC): platelet count usually normal or mildly decreased. In Bernard-Soulier syndrome, thrombocytopenia + giant platelets. PFA-100: prolonged collagen/ADP or collagen/epinephrine closure time. Platelet aggregation tests (light transmission or impedance method): patterns of abnormal response to specific agonists (ADP, collagen, ristocetin, epinephrine, arachidonic acid) are used for diagnosis.
Flow cytometry confirms decreased expression of platelet surface GP IIb/IIIa (CD41/CD61), GP Ib (CD42b), etc. Electron microscopy confirms abnormalities in granule morphology and number (alpha granule deficiency, dense granule deficiency). P-selectin (CD62P) expression testing assesses alpha granule secretory capacity after platelet activation.
Complete blood count (CBC): check platelet count and MPV (mean platelet volume). Blood smear: check platelet size, morphology, and granules. PFA-100 (platelet function analyzer): useful for screening platelet function in whole blood, and a normal PFA-100 result excludes most severe platelet function abnormalities. However, because differentiation from vWD is important, vWF antigen and activity tests are performed together.
Platelet aggregometry: assessment of aggregation responses to various agonists such as ADP, collagen, epinephrine, arachidonic acid, and ristocetin. Flow cytometry: quantification of platelet surface receptor expression such as GP IIb/IIIa (CD41/CD61), GP Ib (CD42b), and P-selectin (CD62P). Dense granule secretory capacity is assessed by ATP release testing (lumiaggregometry).
In patients with bleeding symptoms, a history of taking aspirin, NSAIDs, or antiplatelet drugs must be checked. If the functional abnormality persists even after excluding drug exposure (after discontinuation of aspirin for 7–10 days and clopidogrel for 5 days or more), a congenital disease is suspected.
Glanzmann thrombasthenia: no aggregation to ADP, collagen, epinephrine, or arachidonic acid. Normal aggregation to ristocetin (GP Ib normal). Bernard-Soulier syndrome: absent aggregation to ristocetin. Aggregation to other agonists is decreased but not completely lost. Granule deficiency: primary aggregation to ADP, collagen, etc. is normal; secondary aggregation wave is lost. Aspirin effect: decreased aggregation with arachidonic acid and collagen, partially decreased ADP aggregation.
When a congenital platelet function disorder is suspected, sequencing of the relevant genes (ITGA2B, ITGB3, GP1BA, etc.) or NGS panel testing is performed. Segregation analysis through family studies aids genetic diagnosis. Confirmation of the variant forms the basis for genetic counseling and prenatal diagnosis.
Differentiation is needed from thrombocytopenia (ITP, TTP, HUS), von Willebrand disease (especially type 3), hemophilia (factor VIII/IX deficiency), coagulation factor abnormalities, etc. Comprehensive interpretation of platelet count, coagulation tests, vWF tests, and platelet function tests is important.
Discontinuation of drugs causing bleeding (aspirin, NSAIDs, etc.). Antifibrinolytics (tranexamic acid) are effective for mucosal bleeding (oral, nasal, menstrual, etc.). DDAVP (desmopressin, 0.3 μg/kg intravenously): increases vWF secretion and shortens bleeding time in some platelet function disorders, and is useful particularly for mild platelet function abnormalities and as preoperative treatment. A trial dose in advance is recommended to predict the response.
Platelet transfusion is needed for serious bleeding or surgery. In patients with Glanzmann thrombasthenia or Bernard-Soulier syndrome, repeated transfusions may lead to platelet transfusion refractoriness due to alloimmunization, in which case HLA-matched platelets or crossmatch-compatible platelets are used.
In severe Glanzmann thrombasthenia refractory to platelet transfusion, recombinant FVIIa (NovoSeven) is used. rFVIIa promotes hemostasis by directly increasing thrombin generation on the platelet surface. In Europe, the use of rFVIIa for Glanzmann thrombasthenia is officially approved.
Uremia: dialysis (temporary improvement of platelet function), desmopressin, conjugated estrogens (IV or oral), packed red blood cell transfusion (improves platelet function by increasing hematocrit). Liver cirrhosis: improvement of liver function, platelet transfusion, tranexamic acid. Drug-induced: discontinuation of the causative drug is the most important treatment.
Mild to moderate congenital platelet function disorders have a relatively good prognosis with appropriate prevention and treatment. Severe Glanzmann thrombasthenia carries a risk of early death from bleeding complications (especially intracranial hemorrhage), but survival into adulthood is possible with aggressive treatment and management. Iron overload and alloimmunization from repeated transfusions affect long-term prognosis.
Drug-induced platelet function abnormalities usually normalize when the causative drug is discontinued (about 7–10 days for aspirin, 5 days for clopidogrel), and the prognosis is good. Cases due to systemic diseases such as uremia and liver cirrhosis vary according to the prognosis of the underlying disease, and treatment of the underlying disease is key to improving platelet function.
In patients with platelet function disorders, unnecessary use of aspirin, NSAIDs, and antiplatelet drugs is avoided. Discontinuation of antiplatelet drugs 7–10 days before surgery is considered, and in patients with cardiovascular disease, the thrombotic risk of discontinuation must be carefully assessed.
For patients with congenital platelet function disorders and their families, genetic counseling provides information on the mode of inheritance, recurrence risk, and the availability of prenatal diagnosis. In populations where consanguineous marriage is common, extended family screening may be considered.
Before dental procedures, surgery, or childbirth, preventive measures (tranexamic acid, DDAVP, platelet transfusion on standby) are planned in consultation with a specialist hematologist. Patients and families are educated on how to manage emergency bleeding and how to access medical care, and an emergency card is issued.